ENDOGENOUS OPIOIDS AND OPIATE ANTAGONISTS IN AUTISM: BRIEF REVIEW OF EMPIRICAL FINDINGS AND IMPLICATIONS FOR CLINICIANS
- 1 March 1995
- journal article
- review article
- Published by Wiley in Developmental Medicine and Child Neurology
- Vol. 37 (3), 239-245
- https://doi.org/10.1111/j.1469-8749.1995.tb11998.x
Abstract
Endogenous opioid dysfunction hypotheses for the development of autism are reviewed, along with clinical empirical studies of opiate antagonists in autism and self-injurious behaviour. There is not yet sufficient evidence to suggest the use of opiate antagonists in the treatment of autism. Further research, particularly of natrexone in severe self-injury, is warranted.Keywords
This publication has 30 references indexed in Scilit:
- Autism and Hypomelanosis of Ito in TwinsDevelopmental Medicine and Child Neurology, 1993
- Hypomelanosis of ito is frequently associated with autismEuropean Child & Adolescent Psychiatry, 1992
- Brief report: A double-blind study of naltrexone in infantile autismJournal of Autism and Developmental Disorders, 1992
- Hypomelanosis of Ito in Three Cases with Autism and Autistic-like ConditionsDevelopmental Medicine and Child Neurology, 1991
- B‐endorphin disregulation in autistic and self‐injurious behavior: A neurodevelopmental hypothesisSynapse, 1988
- CSF Monoamines in Autistic Syndromes and Other Pervasive Developmental Disorders of Early ChildhoodThe British Journal of Psychiatry, 1987
- Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autismPediatric Neurology, 1987
- Effects of naloxone on self-injurious behavior: A case studyApplied Research in Mental Retardation, 1983
- Naloxone attenuates self-abusive behavior in developmentally disabled clientsApplied Research in Mental Retardation, 1983
- Serotonin Levels in the Blood and Central Nervous System of a Patient with Sudanophilic LeukodystrophyNeuropediatrics, 1977